We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Immunotherapy is a long-term, preventive treatment that aims to reduce the symptoms of patients diagnosed with hay fever, allergic asthma, conjunctivitis, or allergies to insect stings.
The objective of immunotherapy with allergens is to change the allergic response by inducing immunological tolerance. A patient with allergies has symptoms when they are exposed to the relevant allergen. Immunotherapy uses a larger quantity of the allergen, in combination with a different route of entry into the body. This modifies the immune system's abnormal response, causing it to develop a tolerance to the allergen instead of inflammation and allergic symptoms.
Immunotherapy was originally administered by subcutaneous injection.There are currently liquids or fast-dissolving tablets that can be used in sublingual immunotherapy for certain allergens.
Subcutaneously injected treatments are administered every 4 or 8 weeks; sublingual treatments must be administered daily. This is generally continued over a period of 3 to 5 years. Many patients experience a prolonged protective effect after that period, so an assessment may be made of stopping the immunotherapy.
Immunotherapy is indicated for patients with allergic rhinoconjunctivitis or allergic asthma who:
Immunotherapy with hymenoptera venom is indicated for individuals who experience a severe generalised reaction to bee or wasp stings.
Immunotherapy is generally safe and well tolerated when used in suitably selected patients. Even so, localised and generalised reactions can occur.
The most frequent reactions are localised ones, such as redness or itching at the injection site. These reactions are most likely to occur during the first administration of the treatment, which is why immunotherapy starts at the Allergology Department and, if well tolerated, can be continued on an outpatient basis.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.